Pdt Partners, LLC Editas Medicine, Inc. Transaction History

Pdt Partners, LLC

$1.02 Billion
Q3 2024

A detailed history of Pdt Partners, LLC transactions in Editas Medicine, Inc. stock. As of the latest transaction made, Pdt Partners, LLC holds 39,546 shares of EDIT stock, worth $51,805. This represents 0.01% of its overall portfolio holdings.

Number of Shares

39,546

Previous 246,537 83.96%

Holding current value

$51,805

Previous $1.15 Million 88.36%

% of portfolio

0.01%

Previous 0.12%

26 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$3.39 - $5.96 $701,699 - $1.23 Million	-206,991 Reduced 83.96%	39,546 $134,000
Q2 2024 Aug 15, 2024	BUY	$4.67 - $7.28 $915,511 - $1.43 Million	196,041 Added 388.23%	246,537 $1.15 Million
Q1 2024 May 15, 2024	BUY	$7.03 - $11.07 $354,986 - $558,990	50,496 New	50,496 $374,000
Q3 2023 Nov 14, 2023	BUY	$6.92 - $9.31 $514,668 - $692,421	74,374 Added 90.54%	156,515 $1.22 Million
Q2 2023 Aug 14, 2023	BUY	$6.36 - $11.47 $322,725 - $582,022	50,743 Added 161.61%	82,141 $676,000
Q1 2023 May 15, 2023	SELL	$7.03 - $11.53 $549,760 - $901,669	-78,202 Reduced 71.35%	31,398 $227,000
Q4 2022 Feb 14, 2023	SELL	$8.32 - $13.21 $126,114 - $200,237	-15,158 Reduced 12.15%	109,600 $972,000
Q3 2022 Nov 14, 2022	BUY	$12.16 - $19.42 $459,562 - $733,940	37,793 Added 43.46%	124,758 $1.53 Million
Q2 2022 Aug 15, 2022	BUY	$9.99 - $21.35 $287,352 - $614,111	28,764 Added 49.42%	86,965 $1.03 Million
Q1 2022 May 16, 2022	SELL	$14.08 - $27.63 $677,754 - $1.33 Million	-48,136 Reduced 45.27%	58,201 $1.11 Million
Q4 2021 Feb 14, 2022	BUY	$26.55 - $40.57 $1.04 Million - $1.59 Million	39,137 Added 58.24%	106,337 $2.82 Million
Q3 2021 Nov 15, 2021	SELL	$39.27 - $72.94 $2.42 Million - $4.5 Million	-61,700 Reduced 47.87%	67,200 $2.76 Million
Q2 2021 Aug 16, 2021	BUY	$31.29 - $56.64 $1.91 Million - $3.46 Million	61,111 Added 90.15%	128,900 $7.3 Million
Q1 2021 May 17, 2021	BUY	$39.71 - $90.58 $2.69 Million - $6.14 Million	67,789 New	67,789 $2.85 Million
Q4 2020 Feb 16, 2021	SELL	$27.07 - $84.35 $521,882 - $1.63 Million	-19,279 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$28.06 - $37.16 $540,968 - $716,407	19,279 New	19,279 $541,000
Q2 2020 Aug 14, 2020	SELL	$18.5 - $34.34 $268,453 - $498,307	-14,511 Closed	0 $0
Q1 2020 May 15, 2020	SELL	$14.88 - $32.78 $1.41 Million - $3.1 Million	-94,537 Reduced 86.69%	14,511 $288,000
Q4 2019 Feb 14, 2020	BUY	$19.49 - $32.63 $343,959 - $575,854	17,648 Added 19.31%	109,048 $3.23 Million
Q3 2019 Nov 14, 2019	SELL	$22.49 - $26.81 $1,079 - $1,286	-48 Reduced 0.05%	91,400 $2.08 Million
Q2 2019 Aug 14, 2019	BUY	$20.48 - $27.76 $1.66 Million - $2.25 Million	80,917 Added 768.37%	91,448 $2.26 Million
Q1 2019 May 15, 2019	SELL	$19.43 - $26.41 $1.71 Million - $2.32 Million	-87,943 Reduced 89.31%	10,531 $257,000
Q4 2018 Feb 14, 2019	SELL	$18.19 - $31.79 $927 - $1,621	-51 Reduced 0.05%	98,474 $2.24 Million
Q3 2018 Nov 14, 2018	SELL	$27.65 - $38.39 $1.46 Million - $2.02 Million	-52,638 Reduced 34.82%	98,525 $3.14 Million
Q2 2018 Aug 14, 2018	BUY	$31.4 - $41.01 $7,473 - $9,760	238 Added 0.16%	151,163 $5.42 Million
Q1 2018 May 15, 2018	BUY	$29.84 - $44.08 $4.5 Million - $6.65 Million	150,925 New	150,925 $5 Million

Others Institutions Holding EDIT

# of Institutions

248

Shares Held

57M

Call Options Held

410K

Put Options Held

394K

View Full List

About Editas Medicine, Inc.

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $90M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

More about EDIT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Pdt Partners, LLC with notifications on news.

Account